ArticleFrontiers in medicine2026
Heme arginate improves acute liver failure secondary to erythropoietic protoporphyria: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Erythropoietic protoporphyria (EPP) is a rare inherited disorder with limited therapeutic options. For EPP patients with advanced cholestasis or liver failure, liver transplantation has long been regarded as the definitive therapy to address the hepatic crisis but does not offer a cure. Previous studies have reported that intravenous hemin/hematin may benefit some EPP patients, while the efficacy of intravenous heme arginate in treating EPP remains unreported. Case presentation: We report a 24-year-old male with EPP and severe cholestasis. From 2017 to 2024, the patient was hospitalized eight times for recurrent episodes of jaundice and abdominal pain. These symptoms were effectively alleviated through a comprehensive treatment including artificial liver support (PE + DPMAS), hepatoprotective therapy, and high-glucose infusion. During his latest hospitalization in 2025, artificial liver support failed to improve the liver dysfunction, leading to progressive deterioration to liver failure. Notably, after two doses of intravenous heme arginate, the total bilirubin level gradually declined with significant improvement of ascites, coagulation dysfunction and neuropsychiatric symptoms. The patient was discharged with hepatoprotective therapy and light avoidance with no recurrence at 6-month follow-up. Conclusion: This case suggests that intravenous heme arginate may provide clinical benefit in patients with EPP-associated liver failure and contributes to the limited literature supporting heme-based therapy in treating EPP hepatic crisis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.